Hyperfine (HYPR) Gains from Investment Securities (2025 - 2026)
Hyperfine (HYPR) posted Gains from Investment Securities of $241000.0 for Q1 2026, up 116.46% on a QoQ basis from -$1.5 million in Q4 2025, and up 114.89% year-over-year from $112147.8 in Q1 2025.
Hyperfine (HYPR) Gains from Investment Securities (2025 - 2026) Analysis & Trends
Hyperfine's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $241000.0 for Q1 2026.
- Quarterly Gains from Investment Securities rose 114.89% year-over-year to $241000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 163.91% YoY) and the FY2025 annual result came in at -$825000.0, changed N/A from the prior year.
- Gains from Investment Securities was $241000.0 for Q1 2026 at Hyperfine, up from -$1.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2.3 million in Q3 2025 and bottomed at -$1.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.36 Bn | 175.06 Bn | 6.27 Bn |
| 2 | Stryker | 128.86 Bn | 125.99 Bn | 3.81 Bn |
| 3 | Medtronic | 108.02 Bn | 98.80 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.21 Bn | 66.76 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn |
| 6 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 24.11 Bn | 20.99 Bn | 2.07 Bn |
| 10 | Hyperfine | 94.45 Mn | 53.17 Mn | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 241,000.00 |
| Mar 31, 2026 | 241,000.00 |
| Dec 31, 2025 | -1.46 Mn |
| Dec 31, 2025 | -1.46 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | -46,000.00 |
| Jun 30, 2025 | -46,000.00 |
| Mar 31, 2025 | -1.62 Mn |
| Mar 31, 2025 | -1.62 Mn |